Recombinant HGF was treated only with LASSS (at the same 1:8000 molar ratio to HGF as described earlier, without exposure to peroxynitrire) and then applied to centrifugal ultra-filtration (10-kDa MWCO) to thoroughly wash out un-reacted, free LASSS (FW: 238.39) prior to the c-met binding assay
Oral supplementation with a combination of L-citrulline and L-arginine rapidly increases plasma L-arginine concentration and enhances no bioavailability
Completed the skin irritation test
Gan SJ, Dahlstrom KR, Peck BW, Caywood W, Li G, Wei Q, Zafereo ME , Sturgis EM
Prescribing BPC-157 outside of clinical trials could lead to legal issues for physicians
Nervous system Very common (10% or more): Dysesthesia (up to 22%), headache (up to 17%) Common (1% to 10%): Dizziness, dysgeusia Uncommon (0.1% to 1%): Syncope Postmarketing reports : Headache, dizziness, dysgeusia, dysesthesia Dysesthesia included allodynia, burning sensation, hyperesthesia, hyperpathia, pain of skin, paresthesia, sensitive skin, skin burning sensation, skin discomfort, and skin sensitization